Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.
Zilbermint
Mihail F
MF
Department of Medicine, Saint Agnes Hospital, 900 South Caton Avenue, Box 198, Baltimore, MD 21229, USA.
Dobs
Adrian S
AS
D000577:Amides / Q000494:pharmacology*; D000813:Anilides; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011944:Receptors, Androgen / Q000187:drug effects*
D000577:Amides; D000813:Anilides; D011944:Receptors, Androgen; C547106:ostarine; C034666:propionamide